ASTM » Topics » Neural Regeneration

These excerpts taken from the ASTM 10-K filed Aug 29, 2008.
Neural Regeneration
 
In May 2008, we reprioritized our clinical development programs to primarily focus on cardiovascular applications. We do not anticipate initiating formal clinical trials in the neural area without additional financial resources. While the decision to reprioritize was driven by economic factors, the clinical programs were prioritized based on anticipated time to market and the relative clinical and market potential.
 
We are in the process of developing a proprietary Neural Repair Cell (NRC) product for the treatment of spinal cord injuries and intend to initiate compassionate use patient treatments in the EU when sufficient financial resources are available. We expect that early compassionate use patient treatments will provide clinical experience that will assist us in the development of future clinical protocols.
 
Neural
Regeneration



 



In May 2008, we reprioritized our clinical development programs
to primarily focus on cardiovascular applications. We do not
anticipate initiating formal clinical trials in the neural area
without additional financial resources. While the decision to
reprioritize was driven by economic factors, the clinical
programs were prioritized based on anticipated time to market
and the relative clinical and market potential.


 



We are in the process of developing a proprietary Neural Repair
Cell (NRC) product for the treatment of spinal cord injuries and
intend to initiate compassionate use patient treatments in the
EU when sufficient financial resources are available. We expect
that early compassionate use patient treatments will provide
clinical experience that will assist us in the development of
future clinical protocols.


 




EXCERPTS ON THIS PAGE:

10-K (2 sections)
Aug 29, 2008
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki